BioNTech SE (NASDAQ:BNTX) Short Interest Up 22.3% in November

BioNTech SE (NASDAQ:BNTX) saw a large increase in short interest in November. As of November 15th, there was short interest totalling 2,470,000 shares, an increase of 22.3% from the October 31st total of 2,020,000 shares. Based on an average daily volume of 1,120,000 shares, the short-interest ratio is presently 2.2 days.

Wall Street Analyst Weigh In

A number of research analysts recently commented on BNTX shares. JPMorgan Chase & Co. lowered their price target on BioNTech from $124.00 to $122.00 and set a “neutral” rating on the stock in a report on Tuesday, November 26th. TD Cowen decreased their price objective on BioNTech from $132.00 to $122.00 and set a “hold” rating on the stock in a report on Tuesday, November 5th. Morgan Stanley raised BioNTech from an “equal weight” rating to an “overweight” rating and upped their price objective for the stock from $93.00 to $145.00 in a report on Tuesday, September 24th. Canaccord Genuity Group upped their price objective on BioNTech from $171.00 to $171.44 and gave the stock a “buy” rating in a report on Wednesday, November 27th. Finally, HSBC increased their price target on BioNTech from $97.00 to $136.00 and gave the company a “buy” rating in a report on Monday, October 7th. Four analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $138.67.

Institutional Investors Weigh In On BioNTech

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in BNTX. GAMMA Investing LLC raised its stake in shares of BioNTech by 86.9% in the second quarter. GAMMA Investing LLC now owns 512 shares of the company’s stock worth $41,000 after purchasing an additional 238 shares during the last quarter. EverSource Wealth Advisors LLC grew its holdings in BioNTech by 106.3% in the first quarter. EverSource Wealth Advisors LLC now owns 489 shares of the company’s stock valued at $43,000 after purchasing an additional 252 shares during the period. Planning Capital Management Corp grew its holdings in BioNTech by 45,000.0% in the third quarter. Planning Capital Management Corp now owns 451 shares of the company’s stock valued at $54,000 after purchasing an additional 450 shares during the period. Blue Trust Inc. boosted its stake in shares of BioNTech by 491.1% in the third quarter. Blue Trust Inc. now owns 467 shares of the company’s stock worth $55,000 after acquiring an additional 388 shares during the last quarter. Finally, Daiwa Securities Group Inc. boosted its stake in shares of BioNTech by 430.3% in the second quarter. Daiwa Securities Group Inc. now owns 1,925 shares of the company’s stock worth $155,000 after acquiring an additional 1,562 shares during the last quarter. 15.52% of the stock is currently owned by hedge funds and other institutional investors.

BioNTech Trading Down 1.1 %

BioNTech stock traded down $1.29 during mid-day trading on Monday, hitting $117.10. The company’s stock had a trading volume of 313,511 shares, compared to its average volume of 813,673. BioNTech has a one year low of $76.53 and a one year high of $131.49. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.21 and a current ratio of 7.33. The company has a 50 day moving average of $113.81 and a 200-day moving average of $98.77. The stock has a market cap of $28.07 billion, a PE ratio of -56.68 and a beta of 0.26.

BioNTech (NASDAQ:BNTX) last issued its quarterly earnings data on Monday, November 4th. The company reported $0.81 earnings per share for the quarter, beating analysts’ consensus estimates of ($1.26) by $2.07. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. The company had revenue of $1.24 billion for the quarter, compared to the consensus estimate of $514.08 million. During the same quarter last year, the company earned $0.73 earnings per share. The firm’s revenue for the quarter was up 38.9% compared to the same quarter last year. On average, research analysts anticipate that BioNTech will post -3.72 EPS for the current year.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.